361 Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

361 Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-77,630	Closed	-$1.27M	–	395
2019 Q4	$1.27M	Sell	77,630 -85,703	-52%	-$1.3M	0.35%	134
2019 Q3	$2.17M	Buy	+163,333	New	+$2.28M	0.4%	139
2019 Q1	–	Sell	-85,885	Closed	-$2.24M	–	407
2018 Q4	$2.24M	Buy	85,885 +8,879	+12%	+$209K	0.46%	100
2018 Q3	$1.77M	Buy	+77,006	New	+$1.57M	0.38%	106
2017 Q4	–	Sell	-119,554	Closed	-$2.14M	–	309
2017 Q3	$2.14M	Buy	+119,554	New	+$2M	0.41%	118

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

361 Capital's VNDA Position: Q1 2020 in Review

361 Capital sold out of Vanda Pharmaceuticals (VNDA) in Q1 2020, closing a stake of 77,630 shares — an estimated $1.27M sold.

361 Capital first reported a position in VNDA in Q3 2017 and held it in 5 quarters. The position peaked at $2.24M in Q4 2018. 159 funds tracked by Wall St. Rank hold VNDA as of Q1 2020.

361 Capital reported no remaining Vanda Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
361 Capital sold 77,630 Vanda Pharmaceuticals shares in Q1 2020, an estimated $1.27M.
361 Capital first reported a position in Vanda Pharmaceuticals in Q3 2017 and held it in 5 quarters.
361 Capital's Vanda Pharmaceuticals position peaked at $2.24M in Q4 2018.
159 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2020.

Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.